Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darusentan in resistant systolic hypertension
NCT00364026Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of darusentan in resistant hypertension (RH), sponsored by Gilead Sciences. Started Jun 2004; status: completed.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT00364026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00364026.